Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 11/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21911304 | 0.90 | FFAR2 (0.48) | S1PR3S1PR1TRPV3FFAR2ADRB2 | |
| SCHEMBL12204141 | 0.89 | ADRB2 (0.43) | S1PR3S1PR1S1PR4ADRB2S1PR2 | |
| SCHEMBL25482234 | 0.85 | APLNR (0.46) | TRPV3FFAR2APLNR | |
| SCHEMBL25482260 | 0.84 | S1PR3 (0.47) | S1PR3S1PR1RAB9ASMN1; SMN2S1PR4 | |
| SCHEMBL21910144 | 0.83 | FFAR2 (0.40) | S1PR3S1PR1FFAR2NFE2L2LMNA | |
| SCHEMBL21831494 | 0.79 | LMNA (0.44) | S1PR3S1PR1NFE2L2LMNARAB9A | |
| SCHEMBL23609157 | 0.79 | S1PR3 (0.40) | S1PR3S1PR1NFE2L2LMNARAB9A | |
| SCHEMBL21910133 | 0.79 | CHRM2 (0.40) | S1PR3S1PR1FFAR2NFE2L2LMNA | |
| SCHEMBL12230282 | 0.79 | S1PR3 (0.51) | S1PR3S1PR1S1PR4S1PR2 | |
| SCHEMBL12204733 | 0.79 | S1PR3 (0.34) | S1PR3S1PR1S1PR4ADRB2S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | S1PR3 618/4885S1PR1 563/4885TRPV3 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.